Skip to content
CancerIndex

Publication

MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

Jia-Yao Wang, Yan-Xiang Shao, Li-Li Yang, Hong-Shuai Li, Jia-Qi Liu, Rui-Zhi Liu, Shuang Zhang, Xiang Li, Ji-Yan Liu

Future oncology (London, England)Sep 18, 2026PMID 42757773doi:10.1080/14796694.2026.2732579 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Emerging evidence suggests that combinations of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) may be effective for advanced penile squamous cell carcinoma (PSCC). These findings support the translation of this strategy into the neoadjuvant setting, offering a novel…

Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Candidate 1

Registered trialsNCT07518979

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.